The future of cannabinoids as analgesic agents: A pharmacologic, pharmacokinetic, and pharmacodynamic overview

American Journal of Therapeutics

Volumn 14, Issue 5, 2007, Pages 475-483

  McCarberg, Bill H ^a   Barkin, Robert L ^b,c  

^a KAISER PERMANENTE   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anandamide; Cannabidiol dronabinol; Cannabinoids; Cannabis; Endocannabinoid; Marijuana; Tetrahydrocannabinol

Indexed keywords

AJULEMIC ACID; ANALGESIC AGENT; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; CB1 RECEPTOR AGONIST; DRONABINOL; ENDOCANNABINOID; HERBACEOUS AGENT; NABILONE; PHYTOCANNABINOID; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANXIETY; CENTRAL NERVOUS SYSTEM; CLINICAL STUDY; CLINICAL TRIAL; CLONING; CONFUSION; DATA ANALYSIS; DISEASE ASSOCIATION; DISORIENTATION; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATION; MIGRAINE; NAUSEA; NEUROPATHIC PAIN; NOCICEPTION; PAIN; PARANOIA; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; STANDARDIZATION; VOMITING;

ANALGESICS; CANNABINOIDS; CANNABIS; CLINICAL TRIALS AS TOPIC; ENDOCANNABINOIDS; HUMANS; PHYTOTHERAPY; RECEPTORS, CANNABINOID; TETRAHYDROCANNABINOL;

EID: 34748841430     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3180a5e581     Document Type: Review

References (66)

1. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacology. 2006;105:1-15.
2. Russo EB. History of cannabis as medicine. In: Guy GW, Whittle BA, Robson P, eds. Medicinal uses of cannabis and cannabinoids. London: Pharmaceutical Press; 2004:1-16.
3. U.S. Food and Drug Administration. Guidance for Industry: Botanical Drug Products. Rockville, MD: Center for Drug Evaluation and Research; 2004:48.
4. Pertwee RG. The pharmacology and therapeutic potential of cannabidiol. In: DiMarzo V, ed. Cannabinoids. Dordrecht, Netherlands: Kluwer Academic Publishers; 2004:32-83.
5. Russo EB, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66:234-246.
6. Di Marzo V. Cannabinoids. New York: Springer; 2004.
7. Grotenhermen F. Cannabinoids and the endocannabinoid system. Cannabinoids. 2006;1:10-14.
8. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brain-stem cannabinoid CB2 receptors. Science. 2005;310:329-332.
9. Smart D, Gunthorpe MJ, Derman JC, et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol. 2000;129:227-230.
10. Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA. 2000;97:9561-9566.
11. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA. 2006;103:7895-7900.
12. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharm. 2001;134:845-852.
13. Costa B, Trovato AF, Cornelli F, et al. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharm. 2007;556:75-83.
14. McPartland JM, Russo EB. Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Therapeutics. 2001;1:103-132.
15. Vann RE, Cook CD, Martin BR, et al. Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther. 2007;320:678-686.
16. Cichewicz DL, Martin ZL, Smith FL, et al. Enhancement of mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther. 1999;289:859-867.
17. Cichewicz DL, McCarthy EA. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther. 2003;304:1010-1015.
18. Cichewicz D, Welch SP. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral delta-9- tetrahydrocannabinol. J Pharmacol Exp Ther. 2003;305:812-817.
19. Williams IJ, Edwards S, Rubo A, et al. Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by delta-9- tetrahydrocannabinol. Eur J Pharm. 2006;539:57-63.
20. Maldonado R, Valverde O. Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. Eur Neuropsychopharm. 2003;13:401-410.
21. Lynch MA, Clark AJ. Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. J Pain Sympt Man. 2003;25:496-498.
22. Russo EB. The role of cannabis and cannabinoids in pain management. In: Cole BE, Boswell M, eds. Weiner's Pain Management: A Practical Guide for Clinicians. 7th ed. Boca Raton, FL: CRC Press; 2006:823-844.
23. Volfe Z, Dvilansky A, Nathan I. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res. 1985;5:243-246.
24. Spadone C. Neurophysiologie du cannabis [Neurophysiology of cannabis]. Encephale. 1991;17:17-22.
25. Boger DL, Patterson JE, Jin Q. Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide. Proc Natl Acad Sci USA. 1998;95:4102-4107.
26. Peroutka SJ. Developments in 5-hydroxytryptamine receptor pharmacology in migraine. Neurol Clin. 1990;8:829-839.
27. Peroutka SJ. The pharmacology of current anti-migraine drugs. Headache. 1990;30(Suppl 1):5-11; discussion, 24-28.
28. Russo E. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain. 1998;76:3-8.
29. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol Lett. 2004;25:31-39.
30. Ferri S, Cavicchini E, Romualdi P, et al. Possible mediation of catecholaminergic pathways in the antinociceptive effect of an extract of Cannabis sativa L. Psychopharmacology. 1986;89:244-247.
31. Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. EurJ Pharmacol. 1998;359:1-18.
32. Müller-Vahl KR, Kolbe H, Schneider U, et al. Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand. 1998;98:502-506.
33. Burstein S, Levin E, Varanelli C. Prostaglandins and cannabis. II. Inhibition of biosynthesis by the naturally occurring cannabinoids. Biochem Pharmacol. 1973;22:2905-2910.
34. Schaefer CF, Brackett DJ, Gunn CG, et al. Decreased platelet aggregation following marihuana smoking in man. J Okla State Med Assoc. 1979;72:435-436.
35. Turner CE, Elsohly MA. Biological activity of cannabichromene, its homologs and isomers. J Clin Pharmacol. 1981;21:283S-291S.
36. Evans FJ. Cannabinoids: the separation of central from peripheral effects on a structural basis. Planta Med. 1991;57:S60-S267.
37. Stott CG, Guy GW, Wright S, et al. The effects of cannabis extracts tetranabinex & nabidiolex on human cyclo-oxygenase (COX) activity. Presented at the Symposium on the Cannabinoids, June 2005, Clearwater, FL. International Cannabinoid Research Society; 2005.
38. Klein TW, Friedman H, Specter S. Marijuana, immunity and infection. J Neuroimmunol. 1998;83:102-115.
39. Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA. 2000;97:9561-9566.
40. New York Mayor's Committee on Marihuana, Wallace GB, Cunningham EV. The marihuana problem in the city of New York: sociological, medical, psychological and pharmacological studies. Lancaster, PA: The Jaques Cattell Press; 1944.
41. Douthwaite AH. Choice of drugs in the treatment of duodenal ulcer. Br Med J. 1947;43-47.
42. McPartland JM, Russo EB. Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Therapeutics. 2001;1:103-132.
43. Tambe Y, Tsujiuchi H, Honda G, et al. Gastric cytoprotection of the non-steroidal anti-inflammatory sesquiterpene, beta-caryophyllene. Planta Med. 1996;62:469-470.
44. Tashkin DP. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis. 2005;63:93-100.
45. Gieringer D, St. Laurent J, Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Therapeutics. 2004;4:7-27.
46. Abrams DI, Jay CA, Shade SB, et al. Cannabis in HIV-associated sensory neuropathy: a randomized, placebo-controlled trial. Neurology. 2007;68:515-521.
47. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet. 2003;362:1517-1526.
48. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76:1664-1669.
49. Ernst G, Denke C, Reif M, et al. Standardized cannabis extract in the treatment of postherpetic neuralgia: a randomized, double-blind, placebo-controlled crossover study. Presented at a conference of the International Association for Cannabis as Medicine, September 9, 2005, Leiden, The Netherlands. International Association for Cannabis as Medicine; 2005.
50. Holdcroft A, Maze M, Dore C, et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology. 2006;104:1040-1046.
51. de Meijer E. The breeding of cannabis cultivars for pharmaceutical end uses. In: Guy GW, Whittle BA, Robson P, eds. Medicinal Uses of Cannabis and Cannabinoids. London: Pharmaceutical Press; 2004:55-70.
52. Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehab. 2003;17:18-26.
53. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 "N of 1" studies. Anaesthesia. 2004;59:440-452.
54. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112:299-306.
55. Rog DJ, Nurmiko T, Friede T, et al. Randomized controlled trial of cannabis based medicine in central neuropathic pain due to multiple sclerosis. Neurology. 2005;65:812-819.
56. Nurmikko TJ, Serpell MG, Hoggart B, et al. A multicenter, double-blind, randomized, placebo-controlled trial of oro-mucosal cannabis-based medicine in the treatment of neuropathic pain characterized by allodynia. Presented at a conference of the American Academy of Neurology, April 14, 2005, Miami Beach, FL. American Academy of Neurology; 2005.
57. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434-441.
58. Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45:50-52.
59. Johnson JR, Potts R. Cannabis-based medicines in the treatment of cancer pain: a randomised, double-blind, parallel group, placebo controlled, comparative study of the efficacy, safety and tolerability of Sativex and Tetranabinex in patients with cancer-related pain. Presented at a conference of the British Pain Society, March 8-11, 2005, Edinburgh, Scotland. British Pain Society; 2005.
60. Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12:639-645.
61. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253.
62. Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA. 2003;290:1757-1762.
63. Dyson A, Peacock M, Chen A, et al. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain. 2005;116:129-137.
64. Wiley J. Preclinical assessment of abuse liability of ajulemic acid [letter]. Cannabinoids. 2007;2:3-4.
65. Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med. 2006;7:25-29.
66. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain [in French]. Can J Anaesth. 2006;53:769-775.